Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study

Mult Scler. 2017 Mar;23(3):442-446. doi: 10.1177/1352458516652498. Epub 2016 Jul 11.

Abstract

Background: Alterations of intestinal permeability (IP) may contribute to the pathophysiology of immune-mediated diseases.

Objective: We investigated the possible association between IP changes and multiple sclerosis (MS).

Methods: We studied 22 patients with relapsing-remitting multiple sclerosis (RRMS) and 18 age- and sex-matched healthy donors (HDs), including five twin pairs (one concordant, and four discordant for disease). Measurement of lactulose (L) and mannitol (M; two non-metabolized sugars) levels in urine samples, after an oral load, allowed to quantify gut dysfunction.

Results: The proportion of participants with increased IP was significantly higher in patients than in HDs (16/22 (73%) versus 5/18 (28%); p = 0.001). Accordingly, the L/M urinary ratio showed significantly higher values in patients than in controls ( p = 0.0284). Urinary mannitol concentration was significantly lower in patients than in controls ( p = 0.022), suggesting a deficit of absorption from intestinal lumen. Such changes did not appear related to patients' clinical-radiological features.

Conclusion: The relatively high proportion of IP changes in RR-MS patients seems to confirm our work hypothesis and warrants more work to confirm the result on a larger sample, and to understand the implications for related immunological disturbances and intestinal microbiota alterations. Our finding may also have relevance for oral treatments, recently introduced in clinical practice.

Keywords: Biomarkers; gut absorption; intestinal permeability; microbiota; relapsing–remitting; twins.

MeSH terms

  • Adult
  • Female
  • Gastrointestinal Agents / therapeutic use
  • Gastrointestinal Microbiome / drug effects
  • Gastrointestinal Microbiome / physiology*
  • Humans
  • Lactulose / therapeutic use*
  • Mannitol / therapeutic use*
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Permeability / drug effects
  • Pilot Projects

Substances

  • Gastrointestinal Agents
  • Mannitol
  • Lactulose